Pediatric Sepsis 

  • Author: Shankar Santhanam, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Apr 11, 2012
 

Background

Pediatric sepsis, like sepsis in adults, is generally considered to comprise a spectrum of disorders that result from infection by bacteria, viruses, fungi, or parasites or the toxic products of these microorganisms. (See also Neonatal Sepsis.) The terms bacteremia, viremia, fungemia, and parasitemia refer to bloodstream invasions (BSIs) that may be associated with fever but have no other signs or symptoms of circulatory compromise or end-organ malperfusion or dysfunction.

Sepsis is a problem that presents a management challenge to those who care for infants and children; however, early recognition and intervention clearly improves the outcome for infants and children with infections or intoxications that lead to sepsis.

Most infants and children with sepsis require monitoring and treatment in an intensive care setting. Initial focus should be on stabilization and correction of metabolic, circulatory, and respiratory derangements. Appropriate antimicrobial therapy should be started as soon as possible after evaluation occurs. Ongoing reevaluation is essential.

Critical care expertise is essential for moderate-to-severe cases. Consultation with an infectious diseases specialist may be necessary. Other consultations should be obtained in accordance with the specific clinical circumstances.

Next

Pathophysiology

The spectrum of sepsis ranges from microbial invasion of the bloodstream or intoxication with early signs of circulatory compromise—including tachycardia, tachypnea, peripheral vasodilation, and fever (or hypothermia)—to full-blown circulatory collapse with multiple organ dysfunction syndrome (MODS) and death (see the image below).

Pathogenesis of sepsis and multiple organ dysfunctPathogenesis of sepsis and multiple organ dysfunction syndrome (MODS).

All these manifestations are part of what is more appropriately termed the systemic inflammatory response syndrome (SIRS), which may be caused by noninfectious or infectious conditions. SIRS results from an insult (infectious, traumatic, chemical, malignant, autoimmune, or idiopathic) and the host response to the insult. The outcome depends on the intricate interplay of upregulating and downregulating cytokines and inflammatory cells and the direct effects of the insult itself. Sepsis is SIRS developing in conjunction with infection.

Experts have come together to develop a consensus on definitions of sepsis, SIRS, severe sepsis, and septic shock that are appropriate for the pediatric population.[1] Age-related variables have been applied to the definition of SIRS and sepsis. The definition of SIRS now requires either fever or white blood cell (WBC) abnormality.

The earliest, mildest manifestation of SIRS is typified by the triad of hyperthermia (or hypothermia), tachypnea, and tachycardia. If SIRS is identified and reversed early, the subsequent inflammatory cascade can often be avoided or mitigated. However, in some situations, further damage occurs because the insult or the resultant host immune response is too great. This damage can result in increased cardiac output, peripheral vasodilation, increased tissue oxygen consumption, and a hypermetabolic state (ie, warm shock).

If SIRS is not identified and reversed early, cardiac output may fall, peripheral vascular resistance may increase, and shunting of blood may ensue (ie, cold shock). This results in tissue hypoxia, end-organ dysfunction, metabolic acidosis, end-organ injury or failure, and death.

Previous
Next

Etiology

Bacterial causes

Myriad bacteria, viruses, fungi, and parasites can cause sepsis. Among the bacterial causes of sepsis, the following age-related patterns are observed.

In patients with early-onset neonatal sepsis, Streptococcus agalactiae, Escherichia coli, Haemophilus influenzae, and Listeria monocytogenes are the most frequent organisms encountered.

In patients with late-onset neonatal sepsis, coagulase-negative Staphylococcus, Staphylococcus aureus, E coli, Klebsiella species, Pseudomonas aeruginosa, Enterobacter species, Candida species, S agalactiae, Serratia species, Acinetobacter species, and various anaerobes are some of the most commonly involved organisms.

In most infants worldwide, the most frequent causes of bacterial sepsis are H influenzae type b (Hib), Streptococcus pneumoniae, Neisseria meningitidis, and Salmonella species. In the United States and the developed world, E coli, S aureus, S pneumoniae, and Nmeningitidis predominate because conjugate Hib vaccination has essentially eliminated disease caused by Hib and conjugate pneumococcal vaccination has significantly decreased the incidence of that infection.[2] In regions where malaria occurs, Plasmodium falciparum is a frequent cause of SIRS in infancy.

The same pathogens that cause sepsis in infancy also cause it in childhood, although the presence of encapsulated organisms generally becomes less frequent as a child’s immune response to polysaccharide antigens improves with age.

Risk factors

Underlying conditions predispose to infection with particular pathogens, such as the following:

  • AIDS predisposes to sepsis from various usual and unusual pathogens, particularly pneumococcus
  • Children with hemoglobin SS disease have a 400-fold increased risk of sepsis due to pneumococcus and Salmonella, among other pathogens
  • Congenital heart disease is a risk factor for endocarditis and sepsis, and genitourinary anomalies often increase the risk of urosepsis
  • Infants and children with significant burns are at risk for sepsis caused by skin flora and nosocomial gram-negative pathogens in particular
  • Splenic dysfunction or absence, as well as complement, immunoglobulin, and properdin deficiency, predispose to sepsis due to encapsulated organisms
  • Infants and children with hematologic and solid-organ malignancies (before or during treatment) are at increased risk for sepsis from a considerable variety of organisms
  • Neonates, infants, and children who are hospitalized (particularly in the intensive care unit [ICU]) are at increased risk for SIRS
  • Those with indwelling devices or prosthetic material and other breaches in barrier protective function are also at increased risk for SIRS
Previous
Next

Epidemiology

SIRS remains an infrequent but significant cause of death among infants and children in the United States. The incidence of sepsis is somewhat higher in the developing world than it is in the United States. However, reports are fewer, and precise figures are unavailable.

The risk of sepsis is inversely related to age. Neonates are at the highest risk, with bacterial sepsis occurring in 1-10 per 1000 live births in the United States. No sex predilection for sepsis is known, except for urosepsis, which is more common in females and uncircumcised males. No particular racial predilection is noted for sepsis, except that invasive bacterial infections are more common in Eskimos, American Indians, and individuals with hemoglobin SS disease.

Previous
Next

Prognosis

Mortality from pediatric sepsis ranges from 9% to 35%. Different insults are associated with different outcomes. Host immune status is important in determining outcome. Aggressive fluid resuscitation early in the course of SIRS results in decreased mortality (except, possibly, in resource-limited, developing countries).[3, 4]

Almost half of neonatal deaths are caused by sepsis, although advances in diagnosis and treatment have caused this rate to decrease substantially, especially in preterm infants. Again, mortality tends to decrease as age increases in the pediatric population.

Previous
Next

Patient Education

Parents of newborns should understand that any fever in the first few months of life necessitates immediate evaluation. The importance of fever as a marker of possible serious infection, rather than a concerning symptom itself, should be emphasized.

Front-line providers must recognize the importance of aggressive resuscitation for the patient with early signs of SIRS.

Vaccination is the key to preventing many of these infections. Travelers should be warned of the possibility of serious infections during travel.

For patient education information, see the Infections Center, as well as Sepsis.

Previous
 
 
Contributor Information and Disclosures
Author

Shankar Santhanam, MD  Consulting Staff, Department of Emergency Medicine, Emergency Medical Associates; Consulting Staff, Department of Family Medicine, Capital Health Systems

Shankar Santhanam, MD is a member of the following medical societies: American Academy of Family Physicians and American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: Novartis Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

Itzhak Brook, MD, MSc Professor, Department of Pediatrics, Georgetown University School of Medicine

Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Armed Forces Infectious Diseases Society, Association of Military Surgeons of the US, Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases,

Mark R Schleiss, MD American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. Jan 2005;6(1):2-8. [Medline].

  2. Greenhow TL, Hung YY, Herz AM. Changing epidemiology of bacteremia in infants aged 1 week to 3 months. Pediatrics. Mar 2012;129(3):e590-6. [Medline].

  3. Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med. Jun 30 2011;364(26):2483-95. [Medline].

  4. Myburgh JA. Fluid resuscitation in acute illness--time to reappraise the basics. N Engl J Med. Jun 30 2011;364(26):2543-4. [Medline].

  5. Mancini N, Carletti S, Ghidoli N, Cichero P, Burioni R, Clementi M. The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev. Jan 2010;23(1):235-51. [Medline]. [Full Text].

  6. Rajani AK, Philip AGS. Diagnostic Tests in Neonatology: Evaluation and Interpretation Using Sepsis as an Example. NeoReviews. Jul 2011;12(7):e368-e373.

  7. [Guideline] Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. Jan 2008;34(1):17-60. [Medline]. [Full Text].

  8. [Best Evidence] [Guideline] Yager P, Noviski N. Shock. Pediatr Rev. Aug 2010;31(8):311-8; quiz 319. [Medline].

  9. Larsen GY, Mecham N, Greenberg R. An emergency department septic shock protocol and care guideline for children initiated at triage. Pediatrics. Jun 2011;127(6):e1585-92. [Medline].

  10. Skinner SC, Iocono JA, Ballard HO, Turner MD, Ward AN, Davenport DL, et al. Improved survival in venovenous vs venoarterial extracorporeal membrane oxygenation for pediatric noncardiac sepsis patients: a study of the Extracorporeal Life Support Organization registry. J Pediatr Surg. Jan 2012;47(1):63-7. [Medline].

  11. Rodríguez-Núñez A, López-Herce J, Gil-Antón J, Hernández A, Rey C. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care. Feb 2006;10(1):R20. [Medline]. [Full Text].

  12. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. Oct 7 2009;302(13):1421-8. [Medline].

  13. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. Oct 5 2011;CD007137. [Medline].

  14. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. Jan 2012;129(1):116-23. [Medline].

  15. Haque KN, Pammi M. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. Oct 5 2011;CD004205. [Medline].

  16. FDA Safety Alert. Xigris [drotrecogin alfa (activated)]: Market Withdrawal - Failure to Show Survival Benefit. US Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm277143.htm. Accessed October 26, 2011.

  17. PR Newswire. Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results. Lilly. Available at https://investor.lilly.com/releasedetail2.cfm?ReleaseID=617602. Accessed October 26, 2011.

  18. Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. Jan 2004;113(1 Pt 1):7-17. [Medline].

  19. Weiss KD. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. Jan 2004;113(1 Pt 1):134. [Medline].

Previous
Next
 
Pathogenesis of sepsis and multiple organ dysfunction syndrome (MODS).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.